Merck & Co., Inc. (MRK)
$36.46
1.13 (+3.20%)
| CAPS Rating |
|
|---|---|
| Open | $35.45 |
| Previous Close | $35.33 |
| Daily Range | $35.33 - $36.67 |
| 52-Week Range | $31.25 - $35.72 |
| Market Cap | $76.9B |
| P/E Ratio | 9.25 |
| Dividend (Yield) | 15.00 (5.90%) |
| Volume | 36,365,080 |
| Average Daily Volume | 9,128,000 |
MRK
VS S&P 500 (SPY)
How do you think MRK will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
MRK Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
MRK News and Commentary
- MARKET SNAPSHOT: Investors May Turn Defensive As Fizz Leaves Stocks – SmartMoney
- This Baby Is a Nice Addition – The Motley Fool
- 4-Star Stocks Poised to Pop: Merck – The Motley Fool
- Pfizer Dodges a Bullet – The Motley Fool
- Pfizer's Generic Growth, With a Side of Sashimi – The Motley Fool
- Abbott Hesitates To Promote Niaspan Study Due To FDA Rules – SmartMoney
- Cash for Clunkers: 100% Gainers to Sell Now – The Motley Fool
- Your Heart or Your Stomach? – The Motley Fool
- Drug Lowers Cholesterol; Stock Follows – The Motley Fool
- UPDATE: Study Questions Utility Of Merck Cholesterol Drugs – SmartMoney
- VIVUS Gets a Spark – The Motley Fool
- CORRECT:In Overhaul,Drug Industry Insider Sees 'Good, Bad, Ugly' – SmartMoney
- These Stocks Will Burn You – The Motley Fool
- 5 Stocks Making Cash – The Motley Fool
- In Overhaul, Drug Industry Insider Sees 'Good, Bad And Ugly' – SmartMoney
- CMED Earning Outlook – Blog at The Motley Fool
- Another Study Questions Utility Of Merck Cholesterol Drugs – SmartMoney
- UPDATE: Crestor Cuts Cardiovascular Problems In Women – SmartMoney
- Up 80%, It's Time to Sell – The Motley Fool
- Former Schering CEO Becomes Senior Adviser To Warburg Pincus – SmartMoney
RSS Headlines
Fool UK
